The vascular wall has the capacity to produce thromboxane A 2 . However, the role of vascular thromboxane A 2 is still uncertain. In this study, we examined the relationship between vascular thromboxane A 2 generation and vascular smooth muscle cell growth in spontaneously hypertensive rats (SHR). Vascular thromboxane A 2 generation was significantly enhanced by 49% in 5-week-old and by 117% in 15-week-old SHR as compared with age-matched Wistar-Kyoto rats (WKY). Thromboxane in the prehypertensive stage show hyperplasia or hypertrophy in the cardiovascular system. '-3 Thickening of the vascular wall increases the wall's stiffness and narrows the vascular lumens, thereby producing an elevation of peripheral vascular resistance. Because some humoral substances, such as catecholamines, 4 steroids, 5 platelet-derived growth factor, 6 and insulin, 7 are reported to influence cell proliferation in various cell lines, these factors may be responsible to some extent for the vascular thickness observed in SHR. However, since vascular smooth muscle cells (VSMCs) of SHR From the
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in the prehypertensive stage show hyperplasia or hypertrophy in the cardiovascular system.'- 3 Thickening of the vascular wall increases the wall's stiffness and narrows the vascular lumens, thereby producing an elevation of peripheral vascular resistance. Because some humoral substances, such as catecholamines, 4 steroids, 5 platelet-derived growth factor, 6 and insulin, 7 are reported to influence cell proliferation in various cell lines, these factors may be responsible to some extent for the vascular thickness observed in SHR. However, since vascular smooth muscle cells (VSMCs) of SHR sustain an enhanced proliferative activity even if they are cultured in an artificial medium, alterations of the biological properties of VSMCs are assumed to elicit the thickening of the vascular wall.
The vascular wall produces vasodepressor prostacyclin (PGy. Moreover, some evidence has been provided that vasoconstrictor thromboxane A 2 (TXAJ is produced in the vascular wall. 8 In addition, experimental models of genetic hypertension have been shown to possess an enhanced vascular TXA 2 generation. 9 ' l0 Further, prostaglandins exert an influence on the proliferation of various cells," and thromboxane B 2 (TXB2) stimulates the proliferations of cell lines such as 3T3 cells 12 and melanoma cells. 13 Thus, we propose that enhanced vascular TXA 2 generation to some extent participates in the increase in vascular wall thickness in SHR, which may be partly manifested by hyperplasia of VSMCs. In the present study, to test our hypothesis, we examined vascular TXA 2 generation in SHR and investigated the effects of a TXA 2 synthase inhibitor, OKY 046
propenoate), and a TXA 2 analogue ,9,11 -epithio-11,12-methano-TXA 2 (STA2), on the proliferative activities of cultured VSMCs of SHR and Wistar-Kyoto rats (WKY).
Materials and Methods Experiment 1: Vascular Capacity to Produce
Thromboxane A 2 Twenty-four 5-week-old and twenty 15-week-old SHR and WKY (from the University of Tokyo breeding colony) were used for the experiment. After systolic blood pressures were measured by the tail-cuff method, the rats were killed by decapitation and the descending thoracic aortas were isolated. The aortas were placed in an ice-chilled Dulbecco's phosphate-buffered saline solution (D-PBS), and the surrounding connective tissue was gently removed. The prepared strips were incubated in 3 ml of oxygenized D-PBS (pH 7.4) at 37 °C for 30 minutes. TXA 2 released in the medium was measured in the form of TXB 2 , using a direct radioimmunoassay method previously described. 9 Antiserum was raised in rabbits in our laboratory. Measurements were normalized to the dry tissue weights of aorta.
Experiment 2: Vascular Smooth Muscle Cell Culture
VSMCs were isolated from the thoracic aortas of sixteen 7-week-old SHR and WKY according to the method of Ross.
14 Briefly, thoracic descending aortas were obtained, and the adventitia and intima were carefully stripped off with forceps and gauze. Then, explants of about 5 mm 2 were placed on a 94x21-mm polystyrene dish with the intimal side attached to the dish, and 10 ml of Dulbecco's modified Eagle's medium (DMEM; Gibco Laboratories, Grand Island, New York, USA), supplemented with 20% (vol/vol) fetal calf serum (FCS; Gibco), penicillin (100 U/ml), and streptomycin (100 jig/ml), was gently added. The dishes _were incubated at 37 °C in a humidified atmosphere of 95% air and 5% CO 2 . The cells reached confluency 10 days after the inoculation. They were harvested by brief exposure to Hanks' solution supplemented with 0.05% (wt/vol) trypsin and 0.02% (wt/vol) EDTA and transferred into a new dish. At this stage, the cells were designated as the first passage. The percentage of FCS was switched to 10% (vol/vol) in the subsequent media. Harvesting was repeated when the cell growth reached confluency. VSMCs from Passages 4 to 10 were used in the studies. The VSMCs in culture showed the characteristic "hills and valleys" growth pattern, and the occurrence of cytoplasmic myofilaments was confirmed by electron microscopy.
Measurement of Thromboxane A 2 Generation by Vascular Smooth Muscle Cells
VSMCs in the sixth passage were washed three times with FCS-free D-PBS. Thereafter, VSMCs were cultured in D-PBS or D-PBS supplemented with 10" 6 M arachidonic acid for 1 hour. TXA 2 released in the medium was directly radioimmunoassayed as TXB 2 . The cross-reaction of anti-TXB 2 serum was less than 0.00001% with arachidonic acid. The antiserum was highly specific to TXB 2 , so that other arachidonate metabolites did not interfere with the radioimmunoassay in this experimental condition.
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Measurement of Vascular Smooth Muscle Cell Doubling Time
To assess the doubling time of VSMCs, approximately 5 x 10 4 cells were seeded onto 9-cm 2 dishes with 2 ml of DMEM containing 10% (vol/vol) FCS. After 24 hours, the medium was replaced with DMEM containing 10% (vol/vol) FCS and a given concentration of OKY 046 or STA 2 . The medium was renewed every day. The number of cells was counted using a light microscope before and 48 hours after the addition of the compounds. The doubling time of cultured VSMCs was calculated according to the following equation 15 : doubling time = (t|-ti) x log2/(logN, -logN^). In this expression, t, and t 2 are the times when cell numbers are counted and N, and N 2 are the cell numbers at t| and t 2 , respectively. (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) Ci/mmol) was added to the medium. Twentyfour hours after the incubation, the cells were repeatedly washed with D-PBS without Ca 2+ and Mg 2+ at pH 7.35 and treated with 5% perchloric acid at 4 °C for 30 minutes. The radioactivity in the acid-insoluble fractions was measured by an automatic liquid scintillation counter.
Reagents
The authentic eicosanoids, STA 2 and OKY 046 were courteously offered by Ono Pharmaceutical Co., Osaka, Japan. [ VOL 12, No 1, JULY 1988 Values are means ± SEM. n = number of studies. *p < 0.01, tp < 0.003, tp < 0.001, compared with value for respective control WKY.
Results
Experiment 1
The averaged systolic blood pressures and the averaged dry tissue weights of aortas are given in Table 1 . Five-week-old SHR were still in the prehypertensive stage, although they showed 9% higher systolic blood pressure than the agematched WKY. Fifteen-week-old SHR, which were in the established stage of hypertension, possessed a 41% higher blood pressure than the controls. The difference in averaged systolic blood pressure became greater with age. The dry tissue weight of aorta was significantly increased by 12% for 5-week-old SHR and by 21% for 15-week-old SHR when compared with the respective WKY. Vascular capacities to release TXA 2 in SHR and WKY are depicted in Figure 1 . As shown in the figure, the vascular TXA 2 generation was significantly enhanced by 49% in 5-week-old prehypertensive SHR and by 117% in 15-week-old SHR when compared with the respective control. they were cultured in arachidonate-free medium (8.44 ± 0.28, n = 7, vs 7.83 ± 0.19 pg/10 6 cells/hr, n = 7). As shown in Figure 2 , however, when prostaglandin production was stimulated by 10" Next, to assess whether the increased vascular TXA 2 generation is connected to the rapid proliferation of VSMCs of SHR, we explored the effects of a thromboxane synthase inhibitor, OKY 046, and the effects of a stable TXA 2 analogue, STA 2 , on the proliferation of VSMCs. When OKY 046 (10" 3 M) was added to the culture medium, the doubling time was significantly prolonged in VSMCs of SHR (from 24.4 ± 0.8 to 26.4 ± 1.1 hours), whereas the doubling time of VSMCs of WKY was unaltered (Figure 4) On the other hand, the effects of STA 2 , a stable analogue of TXA 2 , on VSMC growth are given in Figure 5 . STA 2 promoted the incorporation of 
Discussion
The vascular wall has a large capacity to generate vasodepressor prostaglandin, which may participate in blood pressure regulation through direct actions on VSMCs. The vascular wall has been demonstrated to produce small amounts of vasoconstrictor TXA 2 as well. 8 In addition, there is some evidence that vascular TXA 2 production is enhanced in genetically hypertensive rat models (e.g., SHR and Dahl salt-sensitive strains). 9 -l0 In this study, we clearly showed that vascular TXA 2 generation was increased not only in adult hypertensive SHR, but also in 5-week-old prehypertensive SHR, which also showed a marked increase in aortic weight per square centimeter, as compared with the agematched WKY. Moreover, we also demonstrated that the enhanced TXA 2 generation in VSMCs of SHR could be unveiled when prostaglandin production was stimulated by arachidonic acid. VOL 12, No 1, JULY 1988 The elevation of blood pressure brings about growth of the vascular wall. 16 In this context, the difference in averaged blood pressure value could explain the difference in weight of the aorta between SHR and WKY. Five-week-old SHR had markedly heavier aortic walls than the age-matched WKY, although the difference in blood pressure was relatively small. Accordingly, the blood pressure difference alone seems unable to account for the entire difference in the vascular weight between the young SHR and WKY; other factors (e.g., an age factor, hormones, various growth factors derived from platelets or endothelial cells, or sympathetic innervation) may participate in the vascular hypertrophy in SHR.
In conjunction with these results, we tested our hypothesis that the enhanced vascular TXA 2 generation might be responsible to some extent for the increased aortic wall thickness in SHR by using VSMCs of the aortic walls of SHR and WKY. In this study, we clearly demonstrated that VSMCs of SHR possessed increased proliferative activity, as compared with WKY. These results are consistent with the previous work of Yamori et al. 17 Next, we demonstrated that the rapid VSMC growth of SHR was significantly tempered by OKY 046, a specific inhibitor of TXA 2 synthase, although it was not brought back to the normal level of WKY. These results indicate that endogenous vascular TXA 2 is partly responsible for the rapid VSMC growth in SHR and that, besides TXA 2 , other intrinsic factors such as alterations of membranous function 18 are additionally involved in the rapid cell proliferation in SHR. Conversely, STA 2 , a stable analogue of TXA 2 , showed a stimulatory effect on VSMC proliferation in WKY, whereas it was less effective in SHR, the cell proliferation of which was assumed to be maximized through endogenous TXA 2 generation by VSMCs. These results indicate that TXA 2 potentiates the cell growth of vascular smooth muscle and that the enhanced endogenous TXA 2 generation observed in VSMCs of SHR becomes a cause of the rapid VSMC growth in SHR.
The increase of vascular wall thickness contributes to the elevation of high blood pressure.
l9 Thus, enhanced TXA 2 generation may participate in the development of hypertension in SHR through its effects on VSMC growth. Indeed, there is some evidence in vivo that TXA 2 synthase inhibitors (e.g., OKY 046 or UK 38485) ameliorate the development of hypertension in SHR. 20 - 22 Moreover, Purkerson et al. 22 have reported protective effects of OKY 046 against sclerotic changes in renal arterioles of SHR. However, since there are some conflicting studies concerning the hypotensive action of UK 38485, a any conclusions should be withheld until more evidence is accumulated.
The mechanisms for the stimulatory effect of TXA 2 on VSMC growth remain to be elucidated. However, there are at least two possibilities. One is that TXA 2 potentiates various humoral substances that participate in the regulatory mechanism for cell proliferation, such as catecholamines, 4 steroids, 3 platelet-derived growth factor, 6 or insulin. 7 The other possibility is a direct action of TXA 2 on VSMC growth. TXA 2 reportedly raises the intracellular Ca 2+ concentration and triggers the calcium messenger system. 24 Among the members of the calcium messenger system, protein kinase C has been assumed to promote cell proliferation. 25 TXA 2 may influence the activity of protein kinase C through the elevation of cytosolic Ca 2+ concentration or by the activation of phosphoinositidespecific phosphodiesterase, which produces diacylglycerol, an activator of protein kinase C.
In this study, we employed VSMCs of the aortic wall and focused on hyperplasia of aortic smooth muscle cells. The aorta is a kind of conduit for the cardiovascular system, and there may be some distinctions in the biological properties of VSMCs from the aortic wall and those from the peripheral resistant vessels. Moreover, there is much evidence that hypertrophy of VSMCs is a main factor in the increase of vascular wall thickness in SHR. 26 Hence, we may not be able to extrapolate our results to the levels of much smaller arteries, which play a key role in the development of hypertension. Further studies are required to address these questions more directly.
